2.50
Hdl Handle:
http://hdl.handle.net/10541/108783
Title:
Phase II study of nimustine in metastatic soft tissue sarcoma.
Authors:
Wagener, D J; Somers, R; Santoro, A; Verweij, J; Woll, Penella J; Blackledge, G; Schütte, H J; Lentz, M A; Van Glabbeke, M
Abstract:
The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.
Affiliation:
Division of Medical Oncology, Radboud University Hospital, Nijmegen, The Netherlands.
Citation:
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma. 1991, 27 (12):1604-5 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/108783
PubMed ID:
1782068
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWagener, D Jen
dc.contributor.authorSomers, Ren
dc.contributor.authorSantoro, Aen
dc.contributor.authorVerweij, Jen
dc.contributor.authorWoll, Penella Jen
dc.contributor.authorBlackledge, Gen
dc.contributor.authorSchütte, H Jen
dc.contributor.authorLentz, M Aen
dc.contributor.authorVan Glabbeke, Men
dc.date.accessioned2010-08-02T10:17:45Z-
dc.date.available2010-08-02T10:17:45Z-
dc.date.issued1991-
dc.identifier.citationPhase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma. 1991, 27 (12):1604-5 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1782068-
dc.identifier.urihttp://hdl.handle.net/10541/108783-
dc.description.abstractThe EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5, 6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.en
dc.language.isoenen
dc.subjectLiver Canceren
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLeukopenia-
dc.subject.meshLiver Neoplasms-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNimustine-
dc.subject.meshSarcoma-
dc.subject.meshThrombocytopenia-
dc.titlePhase II study of nimustine in metastatic soft tissue sarcoma.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Radboud University Hospital, Nijmegen, The Netherlands.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.